ACRS

Aclaris Therapeutics
$5.51
−$0.06 (−0.99%)Sep 10, 2026
3.6FairMoatMint rating

MoatMint rates Aclaris Therapeutics (ACRS) 3.6 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 1.8 out of 10.

Key metrics

The numbers that frame ACRS today
Market cap
$810.33M
P/E (TTM)
-10.7
EV / FCF
-12.7
Gross margin
12.9%
EV / Sales
96.3
ROIC
-59.2%
Div yield
0%
Debt / equity
0.0
52wk Low
$1.74
52wk High
$6.60

ACRS stock rating

How ACRS scores on quality, value, growth, momentum and financial health
3.6out of 10
Fair overallFair business, expensive price
Quality1.8
Growth1.4
Momentum9.6
Value2.2
Financial Health5.3

Growth

Revenue and earnings trend for ACRS
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about ACRS
Is Aclaris Therapeutics a good buy?
Hold. Aclaris Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Aclaris Therapeutics is selling at a very high price.
What is the market capitalization of ACRS?
Aclaris Therapeutics's market capitalization is $810.33M.
What is the P/E ratio for ACRS stock?
Aclaris Therapeutics's current P/E ratio is -10.7.
What is the 52-week high for ACRS stock?
The 52-week high for Aclaris Therapeutics is $6.60. The current close of $5.51 is 16.6% below that high.
What is the 52-week low for ACRS stock?
The 52-week low for Aclaris Therapeutics is $1.74. The current close of $5.51 is 216.4% above that low.
Does ACRS stock pay dividends?
Aclaris Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for ACRS?
Aclaris Therapeutics's Debt / Equity ratio is 0.